What is UPLIZNA® (inebilizumab-cdon)?

UPLIZNA is a prescription medicine used to treat adults with: Neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquap... anti-aquaporin-4 (AQP4) antibody positive; Immunoglobulin G4-related disease (IgG4-RD); Generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. It is not known if UPLIZNA is safe or effective in children. (Read More).

UPLIZNA was studied as a stand-alone* therapy in the largest NMOSD patient study.

The 28-week study, called N-MOmentum, was a randomized, placebo-controlled study. It included patients from different racial and ethnic backgrounds and was designed to represent the real-world NMOSD patient population.




* Stand-alone therapy: the use of other immunosuppressant drugs to prevent NMOSD attacks were not allowed during the trial.
Randomized: participants were chosen at random to receive either UPLIZNA or a placebo.
Placebo: a substance that has no therapeutic effect and is often used as a control in testing drugs.

In the study, UPLIZNA proved to be an effective treatment to reduce the risk of NMOSD attacks that can lead to permanent disabilities. 

relative reduction in attacks

11% of patients on UPLIZNA had an attack through the first 28 weeks vs 42% on placebo.

(n=161 patients on UPLIZNA; n=52 patients on placebo.)

patients were attack free

at 28 weeks compared to ~6 out of 10 on placebo.

In a patient study, UPLIZNA showed long-term attack reduction.

reduction in annualized NMOSD attack rate§ at 2.5+ years

Patients in the study who stayed on UPLIZNA for at least 2.5 years had 0.03 attacks per year compared to 
~1 attack per year on placebo. The open-label period (OLP) was not blinded, not controlled, and results may appear more favorable because patients with less favorable results may drop out. During the duration of the 4+ year OLP, about 1 in 5 patients discontinued, of which 5 patients (2.3%) discontinued due to adverse events.

(n=168 patients on UPLIZNA)

UPLIZNA reduces NMOSD-related hospitalizations

reduced risk

Patients had a yearly hospitalization rate of 0.11 compared to 0.5 for placebo.

(n=161 on UPLIZNA; n=52 patients on placebo)

§ Annualized attack rate: total number of attacks divided by the amount of time patients in the group were studied, outlining the amount of expected attacks on yearly basis.

Open-label period: an extended study where all patients received UPLIZNA and were aware that they were receiving UPLIZNA. The OLP was not placebo-controlled and was compared to results from the placebo-controlled study.

How UPLIZNA made a difference

Hear other UPLIZNA Patient Stories

I decided it was worth it to try UPLIZNA because it fit my lifestyle.

Christine
switched to UPLIZNA in 2017.
Actual patient compensated for her time.

Individual results may vary.

  • Transcript

    Christine: I work five days a week, full time. I'm a manager at the veterinary office I work at and also a technician.

    Back in 2004, I was on a trip for work, and I started having a strange feeling in my leg. It was like it wasn't listening to what my brain was telling it to do. I made an appointment with my neurologist, and he just said I pulled my back and told me to do exercises. He ignored my symptoms and my pleas, and it took about a month for me to get an MRI on my back. They had thought I had a spinal cord tumor, and they admitted me because I was becoming paralyzed very quickly. I spent two weeks in the hospital. They discharged me from the hospital, but I had to move out of my apartment and move back in with my parents. They had to drive me to physical therapy three days a week. I struggled. I learned to walk again, learned to do things on my own. Finally, about a year into not knowing what was going on, I was tested and my neurologist called me back into the office and told me I had NMOSD.

    Narrator: Neuromyelitis optica spectrum disorder, or NMOSD, is a rare, lifelong autoimmune disease caused by inflammation in the central nervous system (CNS), which is made up of the optic nerve, brain stem and spinal cord.

    Christine: After I was diagnosed, the doctors really didn't tell me much because they really didn't know what to expect. It was so rare. It was very scary. I didn't know what was going to happen.

    Narrator: After her diagnosis, Christine tried many different infusions and medicines.

    Her doctor then suggested UPLIZNA, also known as inebilizumab-cdon.

    UPLIZNA is the only FDA-approved AQP4 antibody positive NMOSD therapy in adults with treatment just two times a year, following two initial doses.

    You should not receive UPLIZNA if you have had a life-threatening infusion reaction to UPLIZNA or if you have an active hepatitis B virus infection, or active or untreated inactive (latent) tuberculosis. Please see additional Important Safety Information later in this video and the Medication Guide available on UPLIZNA.com

    Christine: When my doctor first brought up UPLIZNA to me, he told me it was an IV infusion that depleted your B cells.

    The first time it's given two doses, I think, two weeks apart. And then after that, it's just one infusion every six months. I decided that it would be worth it to try UPLIZNA because it fit my lifestyle.

    I just started a small business last year. I make custom dog collars and I sell them on the Internet and go to local craft shows and sell them.

    IMPORTANT SAFETY INFORMATION

    What is UPLIZNA® (inebilizumab-cdon)?

    UPLIZNA is a prescription medicine used to treat adults with: Neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive; Immunoglobulin G4-related disease (IgG4-RD); Generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. It is not known if UPLIZNA is safe or effective in children.

    Who should not receive UPLIZNA?

    You should not receive UPLIZNA if you have:

    • had a life-threatening infusion reaction to UPLIZNA.
    • an active hepatitis B virus infection.
    • active or untreated inactive (latent) tuberculosis.

    What is the most important information I should know about UPLIZNA?

    UPLIZNA may cause serious side effects, including:

    Infusion reactions. UPLIZNA can cause infusion reactions, including anaphylaxis, that can be serious or may cause you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of UPLIZNA for signs and symptoms of an infusion reaction. Tell your healthcare provider right away if you get any of these symptoms:

    • headache
    • sleepiness
    • fever
    • rash
    • nausea
    • shortness of breath
    • muscle aches
    • palpitations

    If you develop an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion and treat your symptoms.

    Infections. Infections can happen during treatment with UPLIZNA. Tell your healthcare provider right away if you have an infection or get any of these symptoms:

    • painful and frequent urination
    • nasal congestion, runny nose, sore throat, fever, chills, cough, body aches
    • UPLIZNA taken before or after other medicines that weaken the immune system may increase your risk of getting infections.
    • Hepatitis B virus (HBV) reactivation. Before starting treatment with UPLIZNA, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with UPLIZNA. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems, including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving UPLIZNA.
    • Progressive Multifocal Leukoencephalopathy (PML). PML may happen with UPLIZNA. PML is a rare brain infection that leads to death or severe disability. Symptoms of PML may get worse over days to weeks. Call your healthcare provider right away if you get any of these symptoms:
      • weakness on one side of the body
      • changes in your vision
      • confusion
      • loss of coordination in your arms and legs
      • changes in thinking or memory
      • changes in your personality
    • Tuberculosis (TB). TB is caused by an infection in the lungs. Before starting treatment with UPLIZNA, your healthcare provider will check to see if you are at risk for getting TB or have ever had TB.
    • Vaccinations. Certain vaccines, called “live” or “live attenuated” vaccines, are not recommended in people receiving UPLIZNA. Talk to your healthcare provider before receiving any vaccinations. If you have a baby and you were receiving UPLIZNA during pregnancy, it is important to tell your baby’s healthcare provider about your UPLIZNA use so they can decide when your baby should receive any vaccine.

    Before receiving UPLIZNA, tell your healthcare provider about all of your medical conditions, including if you:

    • have or think you have an infection.
    • have ever taken, currently take, or plan to take medicines that affect your immune system, or other treatments for NMOSD, IgG4-RD, or gMG. These medicines may increase your risk of getting an infection.
    • have or have ever had hepatitis B or are a carrier of the hepatitis B virus.
    • have or have ever had tuberculosis.
    • have had a recent vaccination or are scheduled to receive any vaccinations. You should receive any required vaccines at least 4 weeks before you start treatment with UPLIZNA.
    • are pregnant or plan to become pregnant. It is not known if UPLIZNA will harm your unborn baby. Females should use birth control (contraception) during treatment with UPLIZNA and for 6 months after your last infusion of UPLIZNA.
    • are breastfeeding or plan to breastfeed. It is not known if UPLIZNA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive UPLIZNA.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    What are the possible side effects of UPLIZNA?
    UPLIZNA may cause serious side effects, including:

    • low blood cell counts. UPLIZNA may cause a decrease in some types of blood cells. Your healthcare provider will do blood tests to check your blood cell counts.

    The most common side effects include: urinary tract infection and joint pain in patients with NMOSD; urinary tract infection and low white blood cell count in patients with IgG4-RD; headache and infusion-related reaction in patients with gMG. These are not all the possible side effects of UPLIZNA.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Please see UPLIZNA full Prescribing Information, including Medication Guide.

IMPORTANT SAFETY INFORMATION

Who should not receive UPLIZNA?

You should not receive UPLIZNA if you have:

  • had a life-threatening infusion reaction to UPLIZNA.
  • an active hepatitis B virus infection.
  • active or untreated inactive (latent) tuberculosis.

What is the most important information I should know about UPLIZNA?

UPLIZNA may cause serious side effects, including:

Infusion reactions. UPLIZNA can cause infusion reactions, including anaphylaxis, that can be serious or may cause you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of UPLIZNA for signs and symptoms of an infusion reaction. Tell your healthcare provider right away if you get any of these symptoms:

  • headache
  • sleepiness
  • fever
  • rash
  • nausea
  • shortness of breath
  • muscle aches
  • palpitations

If you develop an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion and treat your symptoms.

Infections. Infections can happen during treatment with UPLIZNA. Tell your healthcare provider right away if you have an infection or get any of these symptoms:

  • painful and frequent urination
  • nasal congestion, runny nose, sore throat, fever, chills, cough, body aches
  • UPLIZNA taken before or after other medicines that weaken the immune system may increase your risk of getting infections.
  • Hepatitis B virus (HBV) reactivation. Before starting treatment with UPLIZNA, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with UPLIZNA. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems, including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving UPLIZNA.
  • Progressive Multifocal Leukoencephalopathy (PML). PML may happen with UPLIZNA. PML is a rare brain infection that leads to death or severe disability. Symptoms of PML may get worse over days to weeks. Call your healthcare provider right away if you get any of these symptoms:
  • weakness on one side of the body
  • changes in your vision
  • confusion
  • loss of coordination in your arms and legs
  • changes in thinking or memory
  • changes in your personality
  • Tuberculosis (TB). TB is caused by an infection in the lungs. Before starting treatment with UPLIZNA, your healthcare provider will check to see if you are at risk for getting TB or have ever had TB.
  • Vaccinations. Certain vaccines, called “live” or “live attenuated” vaccines, are not recommended in people receiving UPLIZNA. Talk to your healthcare provider before receiving any vaccinations. If you have a baby and you were receiving UPLIZNA during pregnancy, it is important to tell your baby’s healthcare provider about your UPLIZNA use so they can decide when your baby should receive any vaccine.

Before receiving UPLIZNA, tell your healthcare provider about all of your medical conditions, including if you:

  • have or think you have an infection.
  • have ever taken, currently take, or plan to take medicines that affect your immune system, or other treatments for NMOSD, IgG4-RD or gMG. These medicines may increase your risk of getting an infection. 
  • have or have ever had hepatitis B or are a carrier of the hepatitis B virus.
  • have or have ever had tuberculosis.
  • have had a recent vaccination or are scheduled to receive any vaccinations. You should receive any required vaccines at least 4 weeks before you start treatment with UPLIZNA.
  • are pregnant or plan to become pregnant. It is not known if UPLIZNA will harm your unborn baby. Females should use birth control (contraception) during treatment with UPLIZNA and for 6 months after your last infusion of UPLIZNA.
  • are breastfeeding or plan to breastfeed. It is not known if UPLIZNA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive UPLIZNA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of UPLIZNA?

UPLIZNA may cause serious side effects, including:

  • low blood cell counts. UPLIZNA may cause a decrease in some types of blood cells. Your healthcare provider will do blood tests to check your blood cell counts.

The most common side effects include: urinary tract infection and joint pain in patients with NMOSD; urinary tract infection and low white blood cell count in patients with IgG4-RD; headache and infusion-related reaction in patients with gMG. These are not all the possible side effects of UPLIZNA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

UPLIZNA is a prescription medicine used to treat adults with: Neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive; Immunoglobulin G4-related disease (IgG4-RD); Generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. It is not known if UPLIZNA is safe or effective in children.

IMPORTANT SAFETY INFORMATION

Who should not receive UPLIZNA?

You should not receive UPLIZNA if you have:

  • had a life-threatening infusion reaction to UPLIZNA.
  • an active hepatitis B virus infection.
  • active or untreated inactive (latent) tuberculosis.

What is the most important information I should know about UPLIZNA?

UPLIZNA may cause serious side effects, including:

Infusion reactions. UPLIZNA can cause infusion reactions, including anaphylaxis, that can be serious or may cause you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of UPLIZNA for signs and symptoms of an infusion reaction. Tell your healthcare provider right away if you get any of these symptoms:

  • headache
  • sleepiness
  • fever
  • rash
  • nausea
  • shortness of breath
  • muscle aches
  • palpitations

If you develop an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion and treat your symptoms.

Infections. Infections can happen during treatment with UPLIZNA. Tell your healthcare provider right away if you have an infection or get any of these symptoms:

  • painful and frequent urination
  • nasal congestion, runny nose, sore throat, fever, chills, cough, body aches
  • UPLIZNA taken before or after other medicines that weaken the immune system may increase your risk of getting infections.
  • Hepatitis B virus (HBV) reactivation. Before starting treatment with UPLIZNA, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with UPLIZNA. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems, including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving UPLIZNA.
  • Progressive Multifocal Leukoencephalopathy (PML). PML may happen with UPLIZNA. PML is a rare brain infection that leads to death or severe disability. Symptoms of PML may get worse over days to weeks. Call your healthcare provider right away if you get any of these symptoms:
  • weakness on one side of the body
  • changes in your vision
  • confusion
  • loss of coordination in your arms and legs
  • changes in thinking or memory
  • changes in your personality
  • Tuberculosis (TB). TB is caused by an infection in the lungs. Before starting treatment with UPLIZNA, your healthcare provider will check to see if you are at risk for getting TB or have ever had TB.
  • Vaccinations. Certain vaccines, called “live” or “live attenuated” vaccines, are not recommended in people receiving UPLIZNA. Talk to your healthcare provider before receiving any vaccinations. If you have a baby and you were receiving UPLIZNA during pregnancy, it is important to tell your baby’s healthcare provider about your UPLIZNA use so they can decide when your baby should receive any vaccine.

Before receiving UPLIZNA, tell your healthcare provider about all of your medical conditions, including if you:

  • have or think you have an infection.
  • have ever taken, currently take, or plan to take medicines that affect your immune system, or other treatments for NMOSD, IgG4-RD or gMG. These medicines may increase your risk of getting an infection. 
  • have or have ever had hepatitis B or are a carrier of the hepatitis B virus.
  • have or have ever had tuberculosis.
  • have had a recent vaccination or are scheduled to receive any vaccinations. You should receive any required vaccines at least 4 weeks before you start treatment with UPLIZNA.
  • are pregnant or plan to become pregnant. It is not known if UPLIZNA will harm your unborn baby. Females should use birth control (contraception) during treatment with UPLIZNA and for 6 months after your last infusion of UPLIZNA.
  • are breastfeeding or plan to breastfeed. It is not known if UPLIZNA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive UPLIZNA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of UPLIZNA?

UPLIZNA may cause serious side effects, including:

  • low blood cell counts. UPLIZNA may cause a decrease in some types of blood cells. Your healthcare provider will do blood tests to check your blood cell counts.

The most common side effects include: urinary tract infection and joint pain in patients with NMOSD; urinary tract infection and low white blood cell count in patients with IgG4-RD; headache and infusion-related reaction in patients with gMG. These are not all the possible side effects of UPLIZNA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

UPLIZNA is a prescription medicine used to treat adults with: Neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive; Immunoglobulin G4-related disease (IgG4-RD); Generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. It is not known if UPLIZNA is safe or effective in children.